Upon completion of the video presentation, to finish the activity and claim your credit, please click
here.
This activity has expired, credit is no longer available.
This activity is supported by an educational grant from Genentech.
Understanding the Mechanism of Action for Chimeric Antigen Receptor (CAR) Therapy
Edward Stadtmauer, MD
Abramson Cancer Center, University of Pennsylvania
Patricia A. Mangan, RN, MSN, APRN-BC
Abramson Cancer Center, University of Pennsylvania
Adoptive immunotherapy involves engineering the patient’s own T-cells by artificially equipping them with chimeric antigen receptors (CARs) which then enable them to bind to certain proteins on the surface of malignant cells. Referred to as CAR-T cell therapy, this form of treatment has had stunning results in acute lymphoblastic leukemia (ALL) and lymphoma. Cytokine release syndrome (CRS), which can be severe and involve multi-organ failure, is a major potential toxicity. This program will provide advanced practitioners with cutting edge information about adoptive CAR-T cell immunotherapy, mechanism of action, unique and potentially serious side effects, and how to monitor for and manage CRS.
These CME/CE/CPE accredited activities are jointly provided by
